DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 2,008 filers reported holding DANAHER CORPORATION in Q1 2022. The put-call ratio across all filers is 1.38 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $18,208,307 | +19.3% | 73,391 | +15.4% | 0.13% | +23.8% |
| Q2 2023 | $15,262,320 | -16.0% | 63,593 | -11.8% | 0.10% | -19.8% |
| Q1 2023 | $18,176,117 | -16.0% | 72,116 | -11.6% | 0.13% | -20.6% |
| Q4 2022 | $21,649,779 | +119333.9% | 81,568 | +16.2% | 0.16% | +7.8% |
| Q3 2022 | $18,127 | -99.9% | 70,179 | +12.8% | 0.15% | +14.2% |
| Q2 2022 | $15,780,000 | -65.8% | 62,243 | -60.4% | 0.13% | -52.3% |
| Q1 2022 | $46,138,000 | -7.2% | 157,292 | +4.1% | 0.28% | +5.2% |
| Q4 2021 | $49,721,000 | -63.2% | 151,122 | -66.0% | 0.27% | -65.5% |
| Q3 2021 | $135,233,000 | +15.4% | 444,202 | +1.8% | 0.77% | +9.5% |
| Q2 2021 | $117,153,000 | +59.4% | 436,552 | +33.7% | 0.71% | +49.3% |
| Q1 2021 | $73,476,000 | +8.5% | 326,442 | +7.0% | 0.47% | -8.7% |
| Q4 2020 | $67,742,000 | -12.5% | 304,952 | -15.2% | 0.52% | -17.6% |
| Q3 2020 | $77,459,000 | +32.1% | 359,722 | +8.4% | 0.63% | +15.6% |
| Q2 2020 | $58,658,000 | +194.5% | 331,722 | +130.5% | 0.54% | +134.5% |
| Q1 2020 | $19,920,000 | -32.0% | 143,922 | -24.6% | 0.23% | +27.5% |
| Q4 2019 | $29,304,000 | +63.6% | 190,932 | +54.0% | 0.18% | +51.7% |
| Q3 2019 | $17,908,000 | +52.3% | 123,992 | +50.7% | 0.12% | +27.7% |
| Q2 2019 | $11,757,000 | -57.7% | 82,261 | -60.9% | 0.09% | -62.5% |
| Q1 2019 | $27,785,000 | +7.9% | 210,461 | -15.7% | 0.25% | +14.6% |
| Q4 2018 | $25,755,000 | +32.7% | 249,761 | +39.8% | 0.22% | +61.0% |
| Q3 2018 | $19,413,000 | +43.3% | 178,661 | +30.2% | 0.14% | +47.8% |
| Q2 2018 | $13,545,000 | +304.9% | 137,261 | +301.8% | 0.09% | +300.0% |
| Q1 2018 | $3,345,000 | -47.6% | 34,161 | -50.3% | 0.02% | -43.9% |
| Q4 2017 | $6,382,000 | -74.1% | 68,761 | -76.1% | 0.04% | -61.3% |
| Q3 2017 | $24,684,000 | +319.8% | 287,761 | +313.0% | 0.11% | +112.0% |
| Q2 2017 | $5,880,000 | -50.5% | 69,679 | -49.8% | 0.05% | -53.3% |
| Q1 2017 | $11,878,000 | +13.4% | 138,879 | +3.2% | 0.11% | +4.9% |
| Q4 2016 | $10,476,000 | -1.9% | 134,579 | -1.2% | 0.10% | -8.9% |
| Q3 2016 | $10,683,000 | -6.9% | 136,279 | +20.0% | 0.11% | -11.1% |
| Q2 2016 | $11,471,000 | +25.0% | 113,579 | +17.4% | 0.13% | +23.5% |
| Q1 2016 | $9,180,000 | -35.1% | 96,779 | -36.4% | 0.10% | -11.3% |
| Q4 2015 | $14,144,000 | +6.1% | 152,279 | -2.7% | 0.12% | -3.4% |
| Q3 2015 | $13,334,000 | -26.5% | 156,479 | -26.2% | 0.12% | -9.2% |
| Q2 2015 | $18,143,000 | +0.3% | 211,979 | -0.5% | 0.13% | -2.2% |
| Q1 2015 | $18,090,000 | +2.0% | 213,079 | +2.9% | 0.13% | +16.5% |
| Q4 2014 | $17,743,000 | +3.9% | 207,011 | -7.9% | 0.12% | +3.6% |
| Q3 2014 | $17,074,000 | -4.3% | 224,711 | -0.8% | 0.11% | +3.7% |
| Q2 2014 | $17,833,000 | +8.1% | 226,511 | +3.0% | 0.11% | +1.9% |
| Q1 2014 | $16,490,000 | -4.2% | 219,870 | -1.3% | 0.10% | -1.9% |
| Q4 2013 | $17,206,000 | +24.5% | 222,870 | +11.8% | 0.11% | +25.9% |
| Q3 2013 | $13,820,000 | +9.1% | 199,370 | -0.4% | 0.08% | -14.1% |
| Q2 2013 | $12,671,000 | – | 200,170 | – | 0.10% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |